Search

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Purchasing

Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.

Clinical trials deliver medical breakthroughs – but how do they happen?

Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.

Focus on Alliance Management

Business Resource Groups at Boehringer Ingelheim

Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.

Our Partners: ViraTherapeutics

Protein Degraders: Changing the Game in Cancer Drug Discovery

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

Telemedicine – the standalone study that became the new normal

Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!

Why today’s depression trials demand smart new approaches

Ridgefield Research and Innovation

Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Black innovators contribution to health & wellness throughout the years

Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.

FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US

FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

New Documentary Highlights Ranch’s Commitment to Cattle Health

Interview with Norbert Kraut: How cancer drives us forward

Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies

Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US

EMPA-REG OUTCOME® trial: New analyses show that JARDIANCE reduced the risk of CV death in adults with T2D. View ISI, PI and Med Guide.

A grandmother’s empathy offers a safe space for people with mental health conditions

Supporting the Friendship Bench to improve access to mental healthcare.

OFEV® (nintedanib) Now Available in the United States

Deciphering Circuits in Neuroscience | Boehringer Ingelheim US

Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers